Health Behaviour, Impaired Health, Nutrition Intervention
Conditions
Brief summary
There are many health benefits associated with the consumption of omega-3 dietary fats. Omega-3 fats, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can be found in marine food products such as fatty fish, in fortified products such as eggs and milk, or in dietary supplements such as fish oil. Despite numerous health benefits, it is well documented that most people in Western society are not meeting the recommended daily amounts of EPA and DHA omega-3 fats. The overall objective of this study is to examine whether providing young adults (18-25 years) with personal genetic information changes behavior with regards to omega-3 fat consumption. In order to achieve this objective, study participants will be divided into two groups: 1. Genetic and 2. Non-Genetic. The Genetic Group will be provided with their personalized information regarding a common gene variant in addition to general information regarding the health benefits of omega-3 fats, while the Non-Genetic Group will only receive the general information. Primary outcomes studied will include dietary habits and secondary outcomes include blood markers of cardiometabolic health.
Detailed description
There are many health benefits associated with the consumption of omega-3 dietary fats. Omega-3 fats, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), can be found in marine food products such as fatty fish, in fortified products such as eggs and milk, or in dietary supplements such as fish oil. Despite numerous health benefits, it is well documented that most people in Western society are not meeting the recommended daily amounts of EPA and DHA omega-3 fats. The numerous health benefits associated with omega-3 fats are well documented in scientific literature; however, there are a limited number of studies focused on the health effects of omega-3 fats in emerging adults (18-25 years). Indeed, most research to date has been conducted in older adults, with or without hyperlipidemia. In addition, it is important to consider interventions in emerging adults given that behaviours learned in this life stage can persist later in life. It has also been reported that the diet quality (i.e., amount of fruits, vegetables, whole grains, etc.) is reduced for individuals within this age range; thus highlighting another important reason for targeting this demographic. The combination of genetic and dietary information (i.e., nutrigenetics) has the potential to not only benefit basic research, but also the general population. Therefore, more research is needed to determine if providing individuals with their genetic information has the potential to encourage behaviour changes. So far, several studies have investigated how people may change their behaviour in response to genetic risk information, but none have conducted a nutrigenetic intervention examining if providing personal genetic information alters diet behaviours. The overall objective of this study is to examine whether providing emerging adults with personal genetic information changes their behavior with regards to omega-3 consumption. In order to achieve this objective, study participants will be divided into two groups: 1. Genetic and 2. Non-genetic. The Genetic group will be provided with their personal information for a common gene variant in addition to general information regarding the health benefits of omega-3 fats, while the Non-genetic group will only receive the general information. Primary outcomes studied will include dietary habits and secondary outcomes include blood markers of cardiometabolic health.
Interventions
Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
Sponsors
Study design
Eligibility
Inclusion criteria
* Between the ages of 18-25 years
Exclusion criteria
* Younger than 18 years * Older than 25 years * Allergic to fish and/or shellfish * If the participants are currently consuming high amounts of omega-3 food products * Unable to get to the University of Guelph for study visits (lack of transportation, or lives too far away) * Anticipating a significant change in lifestyle (moving houses, joining the gym, participating in elite athletic activities) * Not comfortable giving blood samples * Taking medication which modifies or changes blood lipid levels * Expecting to become pregnant, pregnant or lactating
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Omega-3 Dietary Intake | Baseline and 12 weeks | Omega-3 fat intake was assessed using food frequency questionnaires. The Canadian Nutrient File (version 2015) was used to assess the amount of EPA and DHA in whole foods (e.g., fish, eggs, poultry). Data corresponds to EPA + DHA (mg /day). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Blood Triglycerides (Physiological Parameter) | baseline and 12 weeks | Triglycerides were measured in fasted serum. Data is reported as mmol/L |
| Change in Omega-3 Index in Blood (Physiological Parameter) | baseline and 12 weeks | Blood fatty acids measured by gas chromatography. Data is reported as a percentage of all detected fatty acids. The omega-3 index is calculated by summing data for 3 omega-3 fats in serum: ALA, EPA, and DHA. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Non-genetic Group General Nutrition related to Omega-3 fats: Individuals in this group were provided with only general nutrition information related to omega-3 fats and health. | 29 |
| Genetic Group Genetic information and Omega-3 fat intake: Individuals in this group were provided with general nutrition information related to omega-3 fats and health, as well as information regarding the impact of a common variant in the FADS1 gene and how this variant influences omega-3 fatty acid profiles. | 28 |
| Total | 57 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Withdrawal by Subject | 1 | 0 |
Baseline characteristics
| Characteristic | Non-genetic Group | Genetic Group | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 29 Participants | 28 Participants | 57 Participants |
| Region of Enrollment Canada | 29 participants | 28 participants | 57 participants |
| Sex: Female, Male Female | 29 Participants | 28 Participants | 57 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 28 | 0 / 28 |
| other Total, other adverse events | 0 / 28 | 0 / 28 |
| serious Total, serious adverse events | 0 / 28 | 0 / 28 |
Outcome results
Omega-3 Dietary Intake
Omega-3 fat intake was assessed using food frequency questionnaires. The Canadian Nutrient File (version 2015) was used to assess the amount of EPA and DHA in whole foods (e.g., fish, eggs, poultry). Data corresponds to EPA + DHA (mg /day).
Time frame: Baseline and 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Non-genetic Group | Omega-3 Dietary Intake | Baseline | 190.16 mg/day | Standard Error 39.21 |
| Non-genetic Group | Omega-3 Dietary Intake | 12 weeks | 395.82 mg/day | Standard Error 70.6 |
| Genetic Group | Omega-3 Dietary Intake | Baseline | 211.50 mg/day | Standard Error 43.16 |
| Genetic Group | Omega-3 Dietary Intake | 12 weeks | 323.23 mg/day | Standard Error 65.27 |
Change in Blood Triglycerides (Physiological Parameter)
Triglycerides were measured in fasted serum. Data is reported as mmol/L
Time frame: baseline and 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Non-genetic Group | Change in Blood Triglycerides (Physiological Parameter) | Baseline | 1.02 mmol/L | Standard Error 0.07 |
| Non-genetic Group | Change in Blood Triglycerides (Physiological Parameter) | 12 weeks | 1.02 mmol/L | Standard Error 0.06 |
| Genetic Group | Change in Blood Triglycerides (Physiological Parameter) | Baseline | 0.9 mmol/L | Standard Error 0.07 |
| Genetic Group | Change in Blood Triglycerides (Physiological Parameter) | 12 weeks | 1.02 mmol/L | Standard Error 0.08 |
Change in Omega-3 Index in Blood (Physiological Parameter)
Blood fatty acids measured by gas chromatography. Data is reported as a percentage of all detected fatty acids. The omega-3 index is calculated by summing data for 3 omega-3 fats in serum: ALA, EPA, and DHA.
Time frame: baseline and 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Non-genetic Group | Change in Omega-3 Index in Blood (Physiological Parameter) | Baseline | 3.97 percentage of total fatty acids in serum | Standard Error 0.12 |
| Non-genetic Group | Change in Omega-3 Index in Blood (Physiological Parameter) | 12 weeks | 4.15 percentage of total fatty acids in serum | Standard Error 0.13 |
| Genetic Group | Change in Omega-3 Index in Blood (Physiological Parameter) | Baseline | 3.86 percentage of total fatty acids in serum | Standard Error 0.11 |
| Genetic Group | Change in Omega-3 Index in Blood (Physiological Parameter) | 12 weeks | 3.97 percentage of total fatty acids in serum | Standard Error 0.11 |